Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Di Maio M, Leighl NB, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R, Favaretto A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C. Di Maio M, et al. Among authors: rossi a. J Thorac Oncol. 2012 Dec;7(12):1830-1844. doi: 10.1097/JTO.0b013e318275b327. J Thorac Oncol. 2012. PMID: 23154555 Free article. Clinical Trial.
ALK inhibitors and advanced non-small cell lung cancer (review).
Rossi A, Maione P, Sacco PC, Sgambato A, Casaluce F, Ferrara ML, Palazzolo G, Ciardiello F, Gridelli C. Rossi A, et al. Int J Oncol. 2014 Aug;45(2):499-508. doi: 10.3892/ijo.2014.2475. Epub 2014 May 29. Int J Oncol. 2014. PMID: 24889366 Review.
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A, Daniele G, Costanzo R, Favaretto AG, Filipazzi V, Rossi A, Gebbia V, Castiglione F, Cavanna L, Maiello E, Sandomenico C, Bonanno L, Piazza E, Maione P, Piccirillo MC, Di Maio M, Rocco G, Gallo C, Perrone F, Gridelli C. Morabito A, et al. Among authors: rossi a. Lung Cancer. 2017 Jun;108:15-21. doi: 10.1016/j.lungcan.2017.02.016. Epub 2017 Feb 27. Lung Cancer. 2017. PMID: 28625627 Clinical Trial.
The potential role of nintedanib in treating colorectal cancer.
Rossi A, Latiano TP, Parente P, Chiarazzo C, Limosani F, Di Maggio G, Maiello E. Rossi A, et al. Expert Opin Pharmacother. 2017 Aug;18(11):1153-1162. doi: 10.1080/14656566.2017.1346086. Epub 2017 Jul 6. Expert Opin Pharmacother. 2017. PMID: 28649871 Review.
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
Gobbini E, Galetta D, Tiseo M, Graziano P, Rossi A, Bria E, Di Maio M, Rossi G, Gregorc V, Riccardi F, Scotti V, Ceribelli A, Buffoni L, Delmonte A, Franchina T, Migliorino MR, Cortinovis D, Pisconti S, Bordi P, Catino A, Maiello E, Arizio F, Novello S; other Co-Authors. Gobbini E, et al. Among authors: rossi a, rossi g. Lung Cancer. 2017 Sep;111:30-37. doi: 10.1016/j.lungcan.2017.06.009. Epub 2017 Jun 16. Lung Cancer. 2017. PMID: 28838394
NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?
Trombetta D, Rossi A, Fabrizio FP, Sparaneo A, Graziano P, Fazio VM, Muscarella LA. Trombetta D, et al. Among authors: rossi a. Curr Med Chem. 2017;24(38):4213-4228. doi: 10.2174/0929867324666170911170554. Curr Med Chem. 2017. PMID: 28901268 Review.
7,239 results